Levetiracetam Solution
Product Images NDC 69452-412

Product Visual Gallery

This gallery contains 8 technical images submitted to the FDA as part of the official labeling for Levetiracetam (NDC 69452-412). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Bionpharma Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Figure (Figure1)

A bar chart showing the percentage of patients for three groups: Placebo (7.4%), Levetiracetam 1,000 mg/day (37.1%), and Levetiracetam 3,000 mg/day (39.6%). The vertical axis represents the % of patients, ranging from 0% to 45%. Each bar is labeled with the respective group and sample size.*

FDA Label Image

Figure (Figure2)

A bar chart showing the percentage of patients related to three groups: Placebo, Levetiracetam 1,000 mg/day, and Levetiracetam 2,000 mg/day. The percentages displayed are 6.3% for placebo, 20.8% for 1,000 mg/day, and 35.2% for 2,000 mg/day, with the number of patients in each group noted below the bars.*

FDA Label Image

Figure (Figure3)

A bar graph comparing the percentage of patients between a placebo group and a Levetiracetam 3,000 mg/day group. The placebo group (N=140) shows 14.4% of patients, while the Levetiracetam group (N=180) shows 39.4% of patients. The y-axis represents the percentage of patients from 0% to 45%.*

FDA Label Image

Figure (Figure4)

A bar chart comparing the percentage of patients in two groups: Placebo (N=97) and Levetiracetam (N=101). The vertical axis represents the percentage of patients, showing 19.6% for the Placebo group and 44.6% for the Levetiracetam group, with an asterisk indicating statistical significance for the Levetiracetam group.*

FDA Label Image

Figure (Figure5)

Bar chart comparing the percentage of patients between a Placebo group (19.6%, N=51) and a Levetiracetam group (43.1%, N=58). The y-axis represents the percentage of patients, and the chart includes an asterisk above the Levetiracetam bar, indicating a significant difference.*

FDA Label Image

Figure (Figure6)

A bar chart comparing the percentage of patients between a placebo group and a Levetiracetam group. The placebo group (N=84) shows about 45.2% of patients, while the Levetiracetam group (N=79) shows 72.2%, with an asterisk indicating statistical significance or emphasis.*

FDA Label Image

Image Description (Image01)

Levetiracetam Oral Solution USP 100 mg/mL label. This 16 fl oz (473 mL) bottle is distributed by Bionpharma Inc. The label includes dosage strength, storage instructions, pharmacist dispensing note, warnings, and contact information for adverse event reporting. The solution is made in India, with NDC 69452-412-88.*

FDA Label Image

Structure (Structure01)

Chemical structure of levetiracetam illustrating its molecular arrangement including a pyrrolidone ring connected to an ethyl group, a hydrogen atom, and a carboxamide group.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.